Literature DB >> 34073735

Validation of Inactivation Methods for Arenaviruses.

Silke Olschewski1, Anke Thielebein1, Chris Hoffmann1, Olivia Blake1, Jonas Müller1, Sabrina Bockholt1,2, Elisa Pallasch1,2, Julia Hinzmann1,2, Stephanie Wurr1,2, Neele Neddersen1, Toni Rieger1, Stephan Günther1,2, Lisa Oestereich1,2.   

Abstract

Several of the human-pathogenic arenaviruses cause hemorrhagic fever and have to be handled under biosafety level 4 conditions, including Lassa virus. Rapid and safe inactivation of specimens containing these viruses is fundamental to enable downstream processing for diagnostics or research under lower biosafety conditions. We established a protocol to test the efficacy of inactivation methods using the low-pathogenic Morogoro arenavirus as surrogate for the related highly pathogenic viruses. As the validation of chemical inactivation methods in cell culture systems is difficult due to cell toxicity of commonly used chemicals, we employed filter devices to remove the chemical and concentrate the virus after inactivation and before inoculation into cell culture. Viral replication in the cells was monitored over 4 weeks by using indirect immunofluorescence and immunofocus assay. The performance of the protocol was verified using published inactivation methods including chemicals and heat. Ten additional methods to inactivate virus in infected cells or cell culture supernatant were validated and shown to reduce virus titers to undetectable levels. In summary, we provide a robust protocol for the validation of chemical and physical inactivation of arenaviruses in cell culture, which can be readily adapted to different inactivation methods and specimen matrices.

Entities:  

Keywords:  arenaviruses; high-risk pathogens; inactivation

Year:  2021        PMID: 34073735     DOI: 10.3390/v13060968

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  25 in total

1.  Virus inactivation by solvent/detergent treatment using Triton X-100 in a high purity factor VIII.

Authors:  Peter L Roberts
Journal:  Biologicals       Date:  2008-09       Impact factor: 1.856

2.  Gamma Irradiation as an Effective Method for Inactivation of Emerging Viral Pathogens.

Authors:  Friederike Feldmann; W Lesley Shupert; Elaine Haddock; Barri Twardoski; Heinz Feldmann
Journal:  Am J Trop Med Hyg       Date:  2019-05       Impact factor: 2.345

3.  A simple method for obtaining highly viable virus from culture supernatant.

Authors:  K Saha; Y C Lin; P K Wong
Journal:  J Virol Methods       Date:  1994-03       Impact factor: 2.014

4.  Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation.

Authors:  L H Elliott; J B McCormick; K M Johnson
Journal:  J Clin Microbiol       Date:  1982-10       Impact factor: 5.948

5.  Physicochemical inactivation of Lassa, Ebola, and Marburg viruses and effect on clinical laboratory analyses.

Authors:  S W Mitchell; J B McCormick
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

6.  International external quality assessment study for molecular detection of Lassa virus.

Authors:  Sergejs Nikisins; Toni Rieger; Pranav Patel; Rolf Müller; Stephan Günther; Matthias Niedrig
Journal:  PLoS Negl Trop Dis       Date:  2015-05-21

Review 7.  The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts.

Authors:  Massinissa Si Mehand; Farah Al-Shorbaji; Piers Millett; Bernadette Murgue
Journal:  Antiviral Res       Date:  2018-09-24       Impact factor: 5.970

8.  Mopeia virus-related arenavirus in natal multimammate mice, Morogoro, Tanzania.

Authors:  Stephan Günther; Guy Hoofd; Remi Charrel; Christina Röser; Beate Becker-Ziaja; Graham Lloyd; Christopher Sabuni; Ron Verhagen; Guido van der Groen; Jan Kennis; Abdul Katakweba; Robert Machang'u; Rhodes Makundi; Herwig Leirs
Journal:  Emerg Infect Dis       Date:  2009-12       Impact factor: 6.883

9.  Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro.

Authors:  Stephan Günther; Marcel Asper; Christina Röser; Luciano K S Luna; Christian Drosten; Beate Becker-Ziaja; Peter Borowski; Huan-Ming Chen; Ramachandra S Hosmane
Journal:  Antiviral Res       Date:  2004-09       Impact factor: 5.970

10.  Analysis of Inactivation of SARS-CoV-2 by Specimen Transport Media, Nucleic Acid Extraction Reagents, Detergents, and Fixatives.

Authors:  Stephen R Welch; Katherine A Davies; Hubert Buczkowski; Nipunadi Hettiarachchi; Nicole Green; Ulrike Arnold; Matthew Jones; Matthew J Hannah; Reah Evans; Christopher Burton; Jane E Burton; Malcolm Guiver; Patricia A Cane; Neil Woodford; Christine B Bruce; Allen D G Roberts; Marian J Killip
Journal:  J Clin Microbiol       Date:  2020-10-21       Impact factor: 5.948

View more
  2 in total

1.  Inactivation Methods for Experimental Nipah Virus Infection.

Authors:  Lina Widerspick; Cecilia Alejandra Vázquez; Linda Niemetz; Michelle Heung; Catherine Olal; András Bencsik; Christoph Henkel; Anneke Pfister; Jesús Emanuel Brunetti; Indre Kucinskaite-Kodze; Philip Lawrence; César Muñoz Fontela; Sandra Diederich; Beatriz Escudero-Pérez
Journal:  Viruses       Date:  2022-05-15       Impact factor: 5.818

2.  Understanding Host-Virus Interactions: Assessment of Innate Immune Responses in Mastomys natalensis Cells after Arenavirus Infection.

Authors:  Nele Marie Brinkmann; Chris Hoffmann; Stephanie Wurr; Elisa Pallasch; Julia Hinzmann; Eleonore Ostermann; Wolfram Brune; Maria Elisabeth Eskes; Lukas Jungblut; Stephan Günther; Ludmilla Unrau; Lisa Oestereich
Journal:  Viruses       Date:  2022-09-08       Impact factor: 5.818

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.